OBJECTIVE:
To highlight the effects incurred in the pharmaco-utilization and in the total expenses for dyspeptic patients by the introduction of a disease-management guideline. METHODS: A retrospective reading of an administrative billing database in the Ravenna Local Health Unit was performed for all health-assisted subjects of 10 GPs who had previously developed and agreed to a clinical guideline to manage dyspeptic patients (Dyspro GPs) as well as by a group of 30 self-regulated GPs (Control GPs). The latter group was selected ex post so as not to be significantly different from the former in terms of personal and patient characteristics. According to anti-dyspeptic treatment, patients were grouped as having had or not prescriptions between 01/01/1999 and 12/31/1999. Dyspeptic subjects were divided as having had or not an earlier anti-dyspeptic treatment (new users/users). The follow-up period lasted 365 days. Randomized controlled studies showed that rabeprazole in active peptic ulcer is comparable to omeprazole and more effective than ranitidine. We performed economic evaluations of rabeprazole, omeprazole and ranitidine in active gastric and duodenal ulcers. METHODS: A decision tree model (DATA 3.0 Treeage Software Inc.) was applied for retrospective analysis of peptic ulcer healing rate in controlled clinical trials of the three drugs. Direct costs of standard treatment in a hospital setting (six and four weeks for gastric and duodenal ulcers respectively) were calculated. They included hospital bills, investigations and drug-acquisition costs. Costminimization and cost-effectiveness analyses were used to evaluate rabeprazole vs. omeprazole and rabeprazole vs ranitidine respectively. To calculate the incremental costeffectiveness ratio, we utilized the rate of improvement in well-being after two weeks of treatment. RESULTS: The direct costs of rabeprazole and ranitidine in active duodenal ulcer were comparable ($261,21 vs $263,28) , but the proton pump inhibitor was significantly more cost-effective than the H2-blocker (incremental cost-effectiveness ratio 0,43 vs 4,66). The difference was due to the higher healing rate and faster effect of rabeprazole. The direct costs of rabeprazole and omeprazole in active duodenal and gastric ulcer were $248,21 vs $266,94 and $311,53 vs $332,77 respectively. The difference was due to lower acquisition cost of rabeprazole. CONCLUSION: Rabeprazole may offer economic advantages over omeprazole and ranitidine in hospital treatment of active gastric and duodenal ulcers.
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